22:38 , Dec 17, 2018 |  BC Extra  |  Company News

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

China's National Medical Products Administration (NMPA) conditionally approved on Monday the first domestic anti-PD-1 mAb, Tuoyi toripalimab (JS001) from Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China), as second-line treatment of melanoma. The news comes as...
23:39 , Dec 14, 2018 |  BC Extra  |  Company News

FDA approves Celltrion's Herceptin biosimilar

FDA approved a BLA for Herceptin biosimilar Herzuma trastuzumab-pkrb from Celltrion Inc. (KOSDAQ:068270) to treat HER2-positive breast cancer. In April, Celltrion received complete response letters from FDA for Herzuma and Truxima rituximab-abbs, its Rituxan biosimilar....
19:18 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Dec. 11 with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant...
13:05 , Dec 11, 2018 |  BC Extra  |  Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Tuesday with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant oncogenes...
13:03 , Dec 11, 2018 |  BC Innovations  |  Emerging Company Profile

Black Diamond: Mapping allostery

Black Diamond Therapeutics Inc. emerged from stealth on Tuesday with a platform to mine and drug baskets of allosteric mutant oncogenes using troves of human sequencing data that contain non-catalytic mutations previously deemed non-actionable. The...
19:05 , Nov 30, 2018 |  BC Week In Review  |  Company News

BeiGene to helm Asian development of Zymeworks’ HER2 antibodies

Zymeworks Inc. (TSX:ZYME; NYSE:ZYME) granted BeiGene Ltd. (HKSE:6160; NASDAQ:BGNE) rights to HER2 antibodies ZW25 and ZW49, which Zymeworks said is part of its strategy to speed development by partnering assets in specific geographies. Zymeworks said...
23:52 , Nov 29, 2018 |  BC Extra  |  Company News

Zai gains China rights to three MacroGenics immuno-oncology compounds

Zai Lab Ltd. (NASDAQ:ZLAB) bulked up its cancer pipeline Thursday by in-licensing Chinese rights to three immuno-oncology compounds from MacroGenics Inc. (NASDAQ:MGNX), including margetuximab, an Fc optimized mAb against HER2 in Phase III testing for...
23:08 , Nov 28, 2018 |  BC Innovations  |  Emerging Company Profile

Cybrexa: pH-based tumor targeting

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors. Cybrexa...
23:31 , Nov 27, 2018 |  BC Extra  |  Company News

BeiGene to helm Asian development of Zymeworks’ HER2 antibodies

Zymeworks Inc. (TSX:ZYME; NYSE:ZYME) granted BeiGene Ltd. (HKSE:6160; NASDAQ:BGNE) rights to HER2 antibodies ZW25 and ZW49, which Zymeworks said is part of its strategy to speed development by partnering assets in specific geographies. Zymeworks said...
19:41 , Nov 21, 2018 |  BioCentury  |  Finance

Alphamab's cancer cash

Alphamab Oncology spun out from Suzhou Alphamab Co. Ltd. and raised more than $100 million in a series A round to advance multiple cancer biologics through clinical testing. Investors in the round, which closed on...